Activating mutations in RAS genes, notably KRASG12C, are pervasive in numerous Collections cancers, presenting formidable challenges to therapy due to their elusive druggability.The landmark discovery of KRASG12C allosteric inhibitors marked a transformative milestone in cancer treatment, resulting in the approval of sotorasib and adagrasib.However, limitations in the depth and duration of response prompted the quest for alternative strategies.Recently, Holderfield et al.
, Wasko et al., and Jiang et al.reported on tri-complex inhibitors, namely RMC-7977 and RMC-6236, targeting activated RAS variants, demonstrating promising preclinical efficacy surpassing adagrasib.These advancments signify a paradigm shift in RAS oncology, Bowl Adapter promising enduring therapeutic benefits and warranting further clinical exploration.